Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | Vice Chairman | May 23, 2022 | May 25, 2022 |
| Avantor, Inc.AVTR · Entity 3546 | Director | May 07, 2026 | May 11, 2026 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Director · Chief Executive Officer | July 28, 2026 | July 30, 2026 |
| Viatris IncVTRS · Entity 3277 | Director | March 06, 2026 | March 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date May 23, 2022 · Filed May 25, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 152,103 |
Ending reported balance
After 2022-05-23 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2022-05-23 · Exercise / conversion · Acquired 46,320 · Balance 198,423 Row 2 · 2022-05-23 · Exercise / conversion · Acquired 11,742 · Balance 210,165 Row 3 · 2022-05-23 · Exercise / conversion · Acquired 21,739 · Balance 231,904 Row 4 · 2022-05-23 · Sale · Disposed 68,196 · Balance 163,708 F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.13 to $151.12 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2022-05-23 · Sale · Disposed 11,605 · Balance 152,103 F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.13 to $151.58 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $114.36 · Expires 2028-02-14 | Direct | 0 |
Reported balance
After 2022-05-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-05-23 · Exercise / conversion · Disposed 46,320 · Balance 0 F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $93.50 · Expires 2030-02-19 | Direct | 38,188 |
Reported balance
After 2022-05-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-05-23 · Exercise / conversion · Disposed 11,742 · Balance 38,188 F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $105.92 · Expires 2031-02-17 | Direct | 43,478 |
Reported balance
After 2022-05-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-05-23 · Exercise / conversion · Disposed 21,739 · Balance 43,478 F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.13 to $151.12 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.13 to $151.58 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.
Avantor, Inc.
Report date May 07, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 85,821 |
Reported balance
After 2026-05-07 transaction · row 1
1 source rowRow 1 · 2026-05-07 · Grant · Acquired 25,270 · Balance 85,821 F1: Reflects a grant of restricted stock units that vests on May 07, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted stock units that vests on May 07, 2027.
Sarepta Therapeutics, Inc.
Report date July 28, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 756,104 |
Reported balance
After 2026-07-28 transaction · row 1
1 source rowRow 1 · 2026-07-28 · Grant · Acquired 756,104 · Balance 756,104 F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in substantially equal installments on an annual basis over four years from the date of grant, subject to the Reporting Person's continued employment. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.74 · Expires 2036-07-28 | Direct | 2,224,342 |
Reported balance
After 2026-07-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-28 · Grant · Acquired 2,224,342 · Balance 2,224,342 F2: Represents the date upon which the first twenty-five percent of the option granted vests. 1/48th of the total granted option vests and becomes exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continued employment. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in substantially equal installments on an annual basis over four years from the date of grant, subject to the Reporting Person's continued employment.
F2: Represents the date upon which the first twenty-five percent of the option granted vests. 1/48th of the total granted option vests and becomes exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continued employment.
Viatris Inc
Report date March 06, 2026 · Filed March 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,031 |
Ending reported balance
After 2026-03-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-06 · Exercise / conversion · Acquired 25,112 · Balance 25,112 Row 2 · 2026-03-06 · Exercise / conversion · Acquired 919 · Balance 26,031 F1: Fractional shares have been rounded up in connection with the settlement described in footnote 3 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-06 · Exercise / conversion · Disposed 25,112 · Balance 0 F2: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 15,890 |
Reported balance
After 2026-03-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-06 · Grant · Acquired 15,890 · Balance 15,890 F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027. |
| Dividend Equivalent UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-06 · Exercise / conversion · Disposed 918.455 · Balance 0 F3: Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on May 12, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. |
Filing footnotes · ownership attribution and instrument terms
F1: Fractional shares have been rounded up in connection with the settlement described in footnote 3 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan.
F2: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026.
F3: Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on May 12, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11.
F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 06, 2022 Filed May 10, 2022 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to Buy) · Derivative | 74,309 | $54.44 Strike: $54.44 | $4,045,381.96 |
DisclosureSEC source: 0001179110-22-002947 · edgar.xml · derivative · entry 16 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,309 shares Expires 2024-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 06, 2022 Filed May 10, 2022 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 13,836 | $151.78 | $2,100,028.08 |
DisclosureSEC source: 0001179110-22-002947 · edgar.xml · nonDerivative · entry 5 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,103 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.58 to $151.95 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 06, 2022 Filed May 10, 2022 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 45,988 | $151.13 | $6,950,166.44 |
DisclosureSEC source: 0001179110-22-002947 · edgar.xml · nonDerivative · entry 4 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,939 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.58 to $151.57 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 06, 2022 Filed May 10, 2022 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 40,176 | $150.10 | $6,030,417.60 |
DisclosureSEC source: 0001179110-22-002947 · edgar.xml · nonDerivative · entry 3 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,927 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.58 to $150.57 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 06, 2022 Filed May 10, 2022 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 25,691 | $54.86 | $1,409,408.26 |
DisclosureSEC source: 0001179110-22-002947 · edgar.xml · nonDerivative · entry 2 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2022 Filed May 10, 2022 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 74,309 | $54.44 | $4,045,381.96 |
DisclosureSEC source: 0001179110-22-002947 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:57 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 1,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-22-000081 · wf-form4_164919221986621.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,473 F1 · kind: Reflects a grant of restricted stock units that vests on May 11, 2022. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 23:08 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 38,857 | $149.54 | $5,810,675.78 |
DisclosureSEC source: 0001179110-22-001829 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,103 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:32 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to Buy) · Derivative | 48,161 | $0.00 Strike: $144.54 | $0.00 |
DisclosureSEC source: 0001179110-22-001507 · edgar.xml · derivative · entry 5 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,161 Underlying: Common Stock · 48,161 shares Expires 2032-02-16 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,054 on February 17, 2023, 16,054 on February 17, 2024, and 16,053 on February 17, 2025. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:32 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 11,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001507 · edgar.xml · nonDerivative · entry 4 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,960 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:32 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 17,468 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001507 · edgar.xml · nonDerivative · entry 3 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,395 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:32 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 10,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001507 · edgar.xml · nonDerivative · entry 2 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,927 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:32 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 48,198 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001507 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,450 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| December 27, 2021 Filed Dec 30, 2021 22:01 UTC | AbbVie Inc. ABBV · Entity 2800 | GiftCommon Stock, $0.01 par value | 583 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-011274 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,252 Read SEC document |
| February 28, 2021 Filed Mar 3, 2021 01:26 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 29,077 | $107.74 | $3,132,755.98 |
DisclosureSEC source: 0001179110-21-002592 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,835 Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:34 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 7,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-21-000093 · wf-form4_161463806896980.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,258 F1 · kind: Reflects a grant of restricted stock units that vests on February 25, 2022. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption(right to buy) · Derivative | 65,217 | $0.00 Strike: $105.92 | $0.00 |
DisclosureSEC source: 0001179110-21-002049 · edgar.xml · derivative · entry 5 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,217 Underlying: Common stock · 65,217 shares Expires 2031-02-17 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,739 on February 18, 2022 21,739 on February 18, 2023, and 21,739 on February 18, 2024. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 17,468 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002049 · edgar.xml · nonDerivative · entry 4 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,912 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 10,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002049 · edgar.xml · nonDerivative · entry 3 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,444 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 8,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002049 · edgar.xml · nonDerivative · entry 2 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,967 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 29,121 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002049 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,402 F1 · shares: . Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:29 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 90,679 | $93.61 | $8,488,461.19 |
DisclosureSEC source: 0001179110-20-010868 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,281 Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 20:54 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 10,022 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-20-000078 · wf-form4_158776162686571.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,022 F1 · kind: Reflects a grant of restricted stock units that vests on April 23, 2021. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:57 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 33,492 | $85.42 | $2,860,886.64 |
DisclosureSEC source: 0001179110-20-002865 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,960 Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 114,566 | $0.00 Strike: $93.50 | $0.00 |
DisclosureSEC source: 0001179110-20-002129 · edgar.xml · derivative · entry 5 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,566 Underlying: Common Stock · 114,566 shares Expires 2030-02-19 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,189 on February 20, 2021, 38,189 on February 20, 2022, and 38,188 on February 20, 2023. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 10,479 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002129 · edgar.xml · nonDerivative · entry 4 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,452 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 8,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002129 · edgar.xml · nonDerivative · entry 3 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,973 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 14,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002129 · edgar.xml · nonDerivative · entry 2 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,408 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 41,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002129 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,419 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:59 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 26,710 | $79.41 | $2,121,041.10 |
DisclosureSEC source: 0001179110-19-003095 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,857 Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:20 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 64,485 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001179110-19-002370 · edgar.xml · derivative · entry 5 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,485 Underlying: Common Stock · 64,485 shares Expires 2029-02-20 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,495 on February 21, 2020, 21,495 on February 21, 2021, and 21,495 on February 21, 2022. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:20 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 8,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002370 · edgar.xml · nonDerivative · entry 4 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,567 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:20 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 14,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002370 · edgar.xml · nonDerivative · entry 3 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,002 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:20 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 15,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002370 · edgar.xml · nonDerivative · entry 2 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,013 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:20 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 21,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002370 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,638 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| August 17, 2018 Filed Aug 21, 2018 20:58 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 29,200 | $97.91 | $2,859,109.24 |
DisclosureSEC source: 0001179110-18-010735 · edgar.xml · nonDerivative · entry 2 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,281 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.44 to $98.22, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 17, 2018 Filed Aug 21, 2018 20:58 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 20,800 | $96.97 | $2,016,951.04 |
DisclosureSEC source: 0001179110-18-010735 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,481 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.43 to $97.43, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:30 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 2,643 | $117.93 | $311,683.70 |
DisclosureSEC source: 0001179110-18-003337 · edgar.xml · nonDerivative · entry 2 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,281 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.91 to $117.94, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:30 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 27,683 | $118.26 | $3,273,791.58 |
DisclosureSEC source: 0001179110-18-003337 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,924 Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:55 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 46,320 | $0.00 Strike: $114.36 | $0.00 |
DisclosureSEC source: 0001179110-18-002300 · edgar.xml · derivative · entry 4 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,320 Underlying: Common Stock · 46,320 shares Expires 2028-02-14 F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 15,440 on February 15, 2019, 15,440 on February 15, 2020, and 15,440 on February 15, 2021. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:55 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 14,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002300 · edgar.xml · nonDerivative · entry 3 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,607 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:55 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 17,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002300 · edgar.xml · nonDerivative · entry 2 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,616 F2 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:55 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 15,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002300 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,297 F1 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 22:26 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 25,633 | $94.69 | $2,427,211.84 |
DisclosureSEC source: 0001179110-17-014053 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,922 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.50 to $94.89, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 21:04 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 21,576 | $66.71 | $1,439,334.96 |
DisclosureSEC source: 0001179110-17-008576 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,555 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 23:14 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 30,699 | $62.22 | $1,910,091.78 |
DisclosureSEC source: 0001179110-17-003707 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,131 Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:53 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 100,100 | $0.00 Strike: $61.36 | $0.00 |
DisclosureSEC source: 0001179110-17-002816 · edgar.xml · derivative · entry 3 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,100 Underlying: Common stock · 100,100 shares Expires 2027-02-15 F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 33,367 on 02/16/2018, 33,366 on 02/16/2019, and 33,367 on 02/16/2020. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:53 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 15,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002816 · edgar.xml · nonDerivative · entry 2 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,830 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:53 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 34,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002816 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,455 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| June 02, 2016 Filed Jun 3, 2016 21:27 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 21,574 | $62.83 | $1,355,494.42 |
DisclosureSEC source: 0001179110-16-025998 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,282 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.